{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:11:59Z","timestamp":1789564319829,"version":"build-2803163510"},"reference-count":38,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To examine the safety of the epidermal growth factor (EGF) receptor antibody panitumumab intravitreally applied in patients with myopic macular degeneration (MMD) or neovascular age\u2010related macular degeneration (AMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with MMD stage 4 underwent repeated intravitreal panitumumab injections in escalating doses, and patients with neovascular AMD received combined intravitreal ranibizumab\/panitumumab injections, with single ranibizumab injections applied in between.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 28 patients. In the first cohort, 11 highly myopic patients with MMD stage 4 (age: 66.8\u2009\u00b1\u20096.3\u2009years) received intravitreal panitumumab injections in doses of 0.6\u2009mg (4 eyes; 1 \u00d7\u20091 injection, 3 \u00d7\u20092 Injections), 1.2\u2009mg (4 eyes; 1 \u00d7\u20091 injection; 2 \u00d7\u20092 injections; 1 \u00d7\u20093 injections) and 1.8\u2009mg (3 eyes; 1 \u00d7\u20091 injection, 2 \u00d7\u20092 injections), respectively, in intervals of 3.6\u2009\u00b1\u20091.8\u2009months (first to second injection), and 4.7\u2009months (second to third injection). At 3.7\u2009\u00b1\u20090.4\u2009years (median: 3.6\u2009years; range: 3.5\u20134.7\u2009years) after the first injection, ten patients were re\u2010examined, with no change in axial length (30.6\u2009\u00b1\u20091.0 vs. 30.7\u2009\u00b1\u20091.3;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.66). A second cohort included 17 eyes with neovascular AMD and receiving bimonthly combined panitumumab\/ranibizumab (1.2\u2009mg\/0.5\u2009mg) injections (mean: 2.4\u2009\u00b1\u20090.5 injections). The mean follow\u2010up period was 11.0\u2009\u00b1\u20091.0\u2009months (median: 11\u2009months; range: 6\u201314\u2009months). In none of the eyes of the first and second cohort, treatment\u2010related systemic or intraocular adverse events were noted. Ocular side effects were hyposphagmata at the injection sites. Signs of intraocular inflammation were not detected in any eye. The morphology of the optic nerve head did not change significantly, nor did the IOP (14.5\u2009\u00b1\u20094.3\u2009mmHg vs. 13.5\u2009\u00b1\u20091.5\u2009mmHg;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.30).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Repeated intravitreal panitumumab applications in various doses, single or combined with ranibizumab, were not associated with severe ocular or systemic side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/aos.70235","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:01:23Z","timestamp":1789563683000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety of intravitreally applied epidermal growth factor receptor antibody panitumumab"],"prefix":"10.1111","author":[{"given":"Mukharram M.","family":"Bikbov","sequence":"first","affiliation":[{"name":"Ufa Eye Research Institute of Bashkir State Medical University  Ufa Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyulli M.","family":"Kazakbaeva","sequence":"additional","affiliation":[{"name":"Ufa Eye Research Institute of Bashkir State Medical University  Ufa Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leisan I.","family":"Gilemzianova","sequence":"additional","affiliation":[{"name":"Ufa Eye Research Institute of Bashkir State Medical University  Ufa Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songhomitra","family":"Panda\u2010Jonas","sequence":"additional","affiliation":[{"name":"Rothschild Foundation Hospital Institut Fran\u00e7ais de Myopie  Paris France"},{"name":"LV Prasad Eye Institute  Hyderabad India"},{"name":"Department of Ophthalmology University Hospital Heidelberg  Heidelberg Germany"},{"name":"Privatpraxis Prof Jonas Und Dr. Panda\u2010Jonas  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology University of Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2972-5227","authenticated-orcid":false,"given":"Jost B.","family":"Jonas","sequence":"additional","affiliation":[{"name":"Rothschild Foundation Hospital Institut Fran\u00e7ais de Myopie  Paris France"},{"name":"LV Prasad Eye Institute  Hyderabad India"},{"name":"Privatpraxis Prof Jonas Und Dr. Panda\u2010Jonas  Heidelberg Germany"},{"name":"Singapore Eye Research Institute, Singapore National Eye Center  Singapore Singapore"},{"name":"Beijing Visual Science and Translational Eye Research Institute (BERI), Beijing Tsinghua Changgung Hospital, Tsinghua Medicine Tsinghua University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2020.02.012"},{"key":"e_1_2_7_3_1","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1097\/IAE.0000000000001043","article-title":"Subretinal fibrosis after antivascular endothelial growth factor therapy in eyes with myopic choroidal neovascularization","volume":"36","author":"Ahn S.J.","year":"2016","journal-title":"Retina"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(91)90233-P"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2023-323383"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-15642-4"},{"key":"e_1_2_7_7_1","doi-asserted-by":"crossref","DOI":"10.3389\/fopht.2025.1641194","article-title":"Intravitreal panitumumab and retinal pigment epithelium proliferation in laser\u2010induced retinal degeneration in rabbits","volume":"5","author":"Bikbov M.M.","year":"2025","journal-title":"Frontiers in Ophthalmology (Lausanne)"},{"key":"e_1_2_7_8_1","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age\u2010related macular degeneration","volume":"364","author":"CATT Research Group","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2026.101273"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2022.09.008"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14080"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202001095RR"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-022-02417-8"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305275"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.12.005"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-199212020-00009"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2015.03.009"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.02.021"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05200-5"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2025.101402"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001464"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.APO.0000578944.25956.8b"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjo.2024.100114"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2012.02414.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01500-2"},{"key":"e_1_2_7_26_1","first-page":"839","article-title":"Growth factor responsiveness of human retinal pigment epithelial cells","volume":"31","author":"Leschey K.H.","year":"1990","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2019.07.018"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002388"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.01.022"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03716-8"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-25189"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.05.009"},{"key":"e_1_2_7_34_1","doi-asserted-by":"crossref","DOI":"10.1186\/s40942-019-0157-z","article-title":"Anterior chamber paracentesis during intravitreal injections in observational trials: effectiveness and safety and effects","volume":"5","author":"Saxena S.","year":"2019","journal-title":"International Journal of Retina and Vitreous"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/1535370215587530"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-021-03514-8"},{"key":"e_1_2_7_37_1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12886-026-04909-3","article-title":"Safety and pharmacokinetics of intravitreally repeatedly injected panitumumab in non\u2010human primates \u2010 a study performed under good laboratory practice","volume":"26","author":"Wang Y.X.","year":"2026","journal-title":"BMC Ophthalmology"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-315763"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1159\/000101926"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.70235","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/aos.70235","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.70235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:01:24Z","timestamp":1789563684000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aos.70235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":38,"alternative-id":["10.1111\/aos.70235"],"URL":"https:\/\/doi.org\/10.1111\/aos.70235","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"2026-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"aos.70235"}}